<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922582</url>
  </required_header>
  <id_info>
    <org_study_id>404-C-201</org_study_id>
    <nct_id>NCT02922582</nct_id>
  </id_info>
  <brief_title>Study of Local Administration of DepoTXA for Reduced Postsurgical Bleeding in Subjects Undergoing TKA</brief_title>
  <official_title>A Randomized, Single-Blind, Active-Controlled, Dose-Ranging Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Local Administration of DepoTXA for Reduced Postsurgical Bleeding in Subjects Undergoing Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, single-blind, active-controlled dose-ranging study in subjects&#xD;
      scheduled to undergo total knee arthroplasty (TKA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 60 subjects (15 per arm) are planned for enrollment. Subjects will be&#xD;
      randomized in a 1:1:1:1 ratio to receive either DepoTXA 400 mg, DepoTXA 800 mg, DepoTXA 1200&#xD;
      mg, or IV TXA (Cyklokapron® 1 gram).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">October 28, 2016</start_date>
  <completion_date type="Actual">November 27, 2017</completion_date>
  <primary_completion_date type="Actual">November 27, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-versus-time Curve From Time 0 Extrapolated to Infinity After Drug Administration</measure>
    <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-versus-time Curve From Time 0 to the Last Collection Time After Drug Administration</measure>
    <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Apparent Terminal Elimination Rate Constant</measure>
    <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Apparent Terminal Elimination Half-life</measure>
    <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary of Neurological Assessments (Proportion of Subjects Who Were Oriented and Proportion of Subjects Who Had Any of the Neurologic Events) at Each Assessed Timepoint</measure>
    <time_frame>12, 24, 36, 48, 60, 72, and 96 hours after study drug administration</time_frame>
    <description>Neurological assessment at 12, 24, 36, 48, 60, 72, and 96 hours after study drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Reoperation Due to Hematoma or Wound Dehiscence</measure>
    <time_frame>Through day 60</time_frame>
    <description>Number of subjects who underwent reoperation due to hematoma or wound dehiscence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Transfusion (Number of Units, Number of Units/Subject, Number of Subjects Transfused)</measure>
    <time_frame>Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 90˚ Passive and Active Knee Flexion</measure>
    <time_frame>24, 48, and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Timed Up-and-Go (TUG) Test</measure>
    <time_frame>Day 1; at approximately 8:00 am and 8:00 pm (±2 hours) daily from Day 2 through hospital discharge; and on Day 7</time_frame>
    <description>Physical therapy assessment (Timed Up-and-Go (TUG) test) was conducted once postsurgically on Day 1; at approximately 8:00 am and 8:00 pm (±2 hours) daily from Day 2 through hospital discharge; and on Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Knee and Thigh Measurements</measure>
    <time_frame>48 hours and Day 7</time_frame>
    <description>Leg difference in change from baseline is calculated by = (Operated Leg Change from Baseline) - (Non-Operated Leg Change from Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of NRS From 0-24 Hours, 0-48 Hours, and 24-48 Hours</measure>
    <time_frame>Preoperative; arrival in Post-Anesthesia Care Unit (PACU); 2, 4, 6, 8, 12, 16, 24, 36, 48 hours, Day 7</time_frame>
    <description>Numerical rating scale (NRS) at rest pain score (0 [no pain] to 10 [worst possible pain]) upon arrival at the PACU; at each in-hospital vital sign assessment beginning with the 2-hour assessment and ending with the 48-hour assessment; and the Day-7 follow-up visit. Summary is provided as area under the curve (AUC) of NRS from timepoint 0 to 24 hours, 0 to 48 hours, and 24 to 48 hours.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>DepoTXA 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg Intracapsular at the end of surgery one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DepoTXA 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg Intracapsular at the end of surgery one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DepoTXA 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200mg Intracapsular at the end of surgery one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Tranexamic acid (TXA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 g of IV TXA at the end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DepoTXA</intervention_name>
    <arm_group_label>DepoTXA 1200mg</arm_group_label>
    <arm_group_label>DepoTXA 400mg</arm_group_label>
    <arm_group_label>DepoTXA 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>IV Tranexamic acid (TXA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, ≥18 years of age at screening.&#xD;
&#xD;
          2. Scheduled to undergo elective unilateral open TKA under general, spinal, or regional&#xD;
             anesthesia.&#xD;
&#xD;
          3. American Society of Anesthesiology (ASA) physical status 1, 2, or 3.&#xD;
&#xD;
          4. Female subject must be surgically sterile; or at least 2 years postmenopausal; or have&#xD;
             a monogamous partner who is surgically sterile; or practicing double-barrier&#xD;
             contraception; or practicing abstinence (must agree to use double-barrier&#xD;
             contraception in the event of sexual activity); or using an insertable, injectable, or&#xD;
             transdermal, contraceptive approved by the FDA for greater than 2 months prior to&#xD;
             screening and commit to the use of an acceptable form of birth control for the&#xD;
             duration of the study and for 30 days after completion of the study.&#xD;
&#xD;
          5. Able to provide informed consent, adhere to the study visit schedule, and complete all&#xD;
             study assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently pregnant, nursing, or planning to become pregnant during the study or within&#xD;
             1 month after study drug administration.&#xD;
&#xD;
          2. Planned concurrent surgical procedure (e.g., bilateral TKA).&#xD;
&#xD;
          3. Prior open knee surgery on ipsilateral knee. Prior arthroscopy is permitted.&#xD;
&#xD;
          4. Subjects taking a medication with a known procoagulant effect (e.g., combination&#xD;
             hormonal contraceptives, Factor IX complex concentrates or anti-inhibitor coagulant&#xD;
             concentrates, or all-trans retinoic acid).&#xD;
&#xD;
          5. Contraindication or hypersensitivity to TXA.&#xD;
&#xD;
          6. History of thrombosis or prior Venous thromboembolism (VTE).&#xD;
&#xD;
          7. Known coagulopathy or active intravascular clotting.&#xD;
&#xD;
          8. Prior myocardial infarction.&#xD;
&#xD;
          9. Prior cardiovascular accident (stroke) or subarachnoid hemorrhage.&#xD;
&#xD;
         10. History of epilepsy.&#xD;
&#xD;
         11. Presence of an intravascular stent.&#xD;
&#xD;
         12. History of impaired kidney function, chronic respiratory disease, rheumatoid&#xD;
             arthritis, coagulopathy, or loss of sensation in extremities.&#xD;
&#xD;
         13. Renal insufficiency (serum creatinine level &gt;2 mg/dL).&#xD;
&#xD;
         14. Anemia (Hb level &lt;10 g/dL).&#xD;
&#xD;
         15. Uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with&#xD;
             study assessments.&#xD;
&#xD;
         16. Acquired defective color vision.&#xD;
&#xD;
         17. Malignancy in the last 2 years, with the exception of non-metastatic basal cell or&#xD;
             squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.&#xD;
&#xD;
         18. Suspected or known history of drug or alcohol abuse within the previous year.&#xD;
&#xD;
         19. Body weight &lt;50 kg (110 pounds) or a body mass index &gt;44 kg/m2.&#xD;
&#xD;
         20. Administration of an investigational drug within 30 days or 5 elimination half-lives&#xD;
             of such investigational drug, whichever is longer, prior to study drug administration,&#xD;
             or planned administration of another investigational product or procedure during the&#xD;
             subject's participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Danesi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ortho Arizona</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kendall Regional Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University/Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <results_first_submitted>September 18, 2020</results_first_submitted>
  <results_first_submitted_qc>December 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2020</results_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02922582/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02922582/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited between October 28, 2016 and October 12, 2017 at 4 US sites. The study was terminated on 27-Nov-2017 due to low enrollment.</recruitment_details>
      <pre_assignment_details>One patient was screened but was not randomized due to not meeting inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DepoTXA 400mg</title>
          <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
        </group>
        <group group_id="P2">
          <title>DepoTXA 800mg</title>
          <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
        </group>
        <group group_id="P3">
          <title>DepoTXA 1200mg</title>
          <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
        </group>
        <group group_id="P4">
          <title>IV Tranexamic Acid (TXA)</title>
          <description>1 g of IV TXA at the end of surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set: All subjects who received study drug</population>
      <group_list>
        <group group_id="B1">
          <title>DepoTXA 400mg</title>
          <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
        </group>
        <group group_id="B2">
          <title>DepoTXA 800mg</title>
          <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
        </group>
        <group group_id="B3">
          <title>DepoTXA 1200mg</title>
          <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
        </group>
        <group group_id="B4">
          <title>IV Tranexamic Acid (TXA)</title>
          <description>1 g of IV TXA at the end of surgery</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="7.12"/>
                    <measurement group_id="B2" value="66" spread="1.73"/>
                    <measurement group_id="B3" value="59.3" spread="5.38"/>
                    <measurement group_id="B4" value="58.0" spread="6.16"/>
                    <measurement group_id="B5" value="61.8" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-versus-time Curve From Time 0 Extrapolated to Infinity After Drug Administration</title>
        <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
        <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-versus-time Curve From Time 0 Extrapolated to Infinity After Drug Administration</title>
          <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46462.15" spread="6935.828"/>
                    <measurement group_id="O2" value="106422.7" spread="42128.84"/>
                    <measurement group_id="O3" value="148806.2" spread="14137.74"/>
                    <measurement group_id="O4" value="134602.2" spread="29975.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-versus-time Curve From Time 0 to the Last Collection Time After Drug Administration</title>
        <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
        <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-versus-time Curve From Time 0 to the Last Collection Time After Drug Administration</title>
          <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43784.71" spread="6463.220"/>
                    <measurement group_id="O2" value="104546.5" spread="42813.20"/>
                    <measurement group_id="O3" value="143562.9" spread="13931.94"/>
                    <measurement group_id="O4" value="131153.0" spread="27286.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)</title>
        <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
        <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)</title>
          <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2775.0" spread="741.96"/>
                    <measurement group_id="O2" value="7722.0" spread="2015.25"/>
                    <measurement group_id="O3" value="9827.0" spread="1545.83"/>
                    <measurement group_id="O4" value="125390.0" spread="154587.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax)</title>
        <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
        <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax)</title>
          <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.55"/>
                    <measurement group_id="O2" value="1.5" spread="0.57"/>
                    <measurement group_id="O3" value="2.5" spread="0.96"/>
                    <measurement group_id="O4" value="0.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Apparent Terminal Elimination Rate Constant</title>
        <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
        <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>The Apparent Terminal Elimination Rate Constant</title>
          <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" spread="0.0084"/>
                    <measurement group_id="O2" value="0.035" spread="0.0120"/>
                    <measurement group_id="O3" value="0.035" spread="0.0095"/>
                    <measurement group_id="O4" value="0.136" spread="0.0261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Apparent Terminal Elimination Half-life</title>
        <time_frame>Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.</time_frame>
        <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>The Apparent Terminal Elimination Half-life</title>
          <population>Pharmacokinetic (PK) analysis set: All subjects who received study drug, provided sufficient samples to allow for calculation of PK parameters required for analysis, and who did not have significant protocol deviations</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.679" spread="2.6980"/>
                    <measurement group_id="O2" value="21.132" spread="7.2508"/>
                    <measurement group_id="O3" value="20.956" spread="5.7276"/>
                    <measurement group_id="O4" value="5.220" spread="0.8540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Neurological Assessments (Proportion of Subjects Who Were Oriented and Proportion of Subjects Who Had Any of the Neurologic Events) at Each Assessed Timepoint</title>
        <description>Neurological assessment at 12, 24, 36, 48, 60, 72, and 96 hours after study drug administration</description>
        <time_frame>12, 24, 36, 48, 60, 72, and 96 hours after study drug administration</time_frame>
        <population>Safety analysis set: All subjects who received study drug treatment</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Neurological Assessments (Proportion of Subjects Who Were Oriented and Proportion of Subjects Who Had Any of the Neurologic Events) at Each Assessed Timepoint</title>
          <description>Neurological assessment at 12, 24, 36, 48, 60, 72, and 96 hours after study drug administration</description>
          <population>Safety analysis set: All subjects who received study drug treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects who had any of the neurologic events at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had any of the neurologic events at 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had any of the neurologic events at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had any of the neurologic events at 36 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had any of the neurologic events at 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had any of the neurologic events at 60 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had any of the neurologic events at 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had any of the neurologic events at 96 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Reoperation Due to Hematoma or Wound Dehiscence</title>
        <description>Number of subjects who underwent reoperation due to hematoma or wound dehiscence</description>
        <time_frame>Through day 60</time_frame>
        <population>Safety analysis set: All subjects who received study drug treatment</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Reoperation Due to Hematoma or Wound Dehiscence</title>
          <description>Number of subjects who underwent reoperation due to hematoma or wound dehiscence</description>
          <population>Safety analysis set: All subjects who received study drug treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Transfusion (Number of Units, Number of Units/Subject, Number of Subjects Transfused)</title>
        <time_frame>Day 60</time_frame>
        <population>Efficacy analysis set: All subjects who received study drug and underwent planned surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Transfusion (Number of Units, Number of Units/Subject, Number of Subjects Transfused)</title>
          <population>Efficacy analysis set: All subjects who received study drug and underwent planned surgery.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 90˚ Passive and Active Knee Flexion</title>
        <time_frame>24, 48, and 72 hours</time_frame>
        <population>Efficacy analysis set: All subjects who received study drug and underwent planned surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 90˚ Passive and Active Knee Flexion</title>
          <population>Efficacy analysis set: All subjects who received study drug and underwent planned surgery.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects who had 90˚ active knee flexion at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had 90˚ active knee flexion at 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had 90˚ active knee flexion at 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had 90˚ passive knee flexion at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had 90˚ passive knee flexion at 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who had 90˚ passive knee flexion at 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Complete Timed Up-and-Go (TUG) Test</title>
        <description>Physical therapy assessment (Timed Up-and-Go (TUG) test) was conducted once postsurgically on Day 1; at approximately 8:00 am and 8:00 pm (±2 hours) daily from Day 2 through hospital discharge; and on Day 7</description>
        <time_frame>Day 1; at approximately 8:00 am and 8:00 pm (±2 hours) daily from Day 2 through hospital discharge; and on Day 7</time_frame>
        <population>Efficacy analysis set: All subjects who received study drug and underwent planned surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Timed Up-and-Go (TUG) Test</title>
          <description>Physical therapy assessment (Timed Up-and-Go (TUG) test) was conducted once postsurgically on Day 1; at approximately 8:00 am and 8:00 pm (±2 hours) daily from Day 2 through hospital discharge; and on Day 7</description>
          <population>Efficacy analysis set: All subjects who received study drug and underwent planned surgery.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="4.25"/>
                    <measurement group_id="O2" value="18.1" spread="10.73"/>
                    <measurement group_id="O3" value="14.6" spread="8.97"/>
                    <measurement group_id="O4" value="15.4" spread="6.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="NA">1 participant only</measurement>
                    <measurement group_id="O2" value="80.0" spread="NA">1 participant only</measurement>
                    <measurement group_id="O3" value="40.0" spread="7.07"/>
                    <measurement group_id="O4" value="80.0" spread="NA">1 participant only</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - AM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" spread="10.61"/>
                    <measurement group_id="O2" value="90.0" spread="7.07"/>
                    <measurement group_id="O3" value="66.7" spread="23.63"/>
                    <measurement group_id="O4" value="85.0" spread="21.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2- PM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" spread="14.14"/>
                    <measurement group_id="O2" value="85.0" spread="7.07"/>
                    <measurement group_id="O3" value="69.0" spread="25.94"/>
                    <measurement group_id="O4" value="41.0" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 -Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="6.03"/>
                    <measurement group_id="O2" value="51.1" spread="32.85"/>
                    <measurement group_id="O3" value="61.3" spread="31.76"/>
                    <measurement group_id="O4" value="40.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="11.64"/>
                    <measurement group_id="O2" value="51.2" spread="32.89"/>
                    <measurement group_id="O3" value="32.3" spread="15.72"/>
                    <measurement group_id="O4" value="13.1" spread="NA">1 participant only</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Knee and Thigh Measurements</title>
        <description>Leg difference in change from baseline is calculated by = (Operated Leg Change from Baseline) - (Non-Operated Leg Change from Baseline)</description>
        <time_frame>48 hours and Day 7</time_frame>
        <population>Efficacy analysis set: All subjects who received study drug and underwent planned surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Knee and Thigh Measurements</title>
          <description>Leg difference in change from baseline is calculated by = (Operated Leg Change from Baseline) - (Non-Operated Leg Change from Baseline)</description>
          <population>Efficacy analysis set: All subjects who received study drug and underwent planned surgery.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leg Difference in Change from Baseline in Thigh Circumference (cm) at 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="4.73"/>
                    <measurement group_id="O2" value="6.7" spread="6.37"/>
                    <measurement group_id="O3" value="3.4" spread="4.54"/>
                    <measurement group_id="O4" value="6.1" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Difference in Change from Baseline in Thigh Circumference (cm) at Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.70"/>
                    <measurement group_id="O2" value="5.2" spread="6.17"/>
                    <measurement group_id="O3" value="0.8" spread="5.09"/>
                    <measurement group_id="O4" value="3.3" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Difference in Change from Baseline in Knee Circumference at 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="3.47"/>
                    <measurement group_id="O2" value="5.8" spread="5.37"/>
                    <measurement group_id="O3" value="2.2" spread="4.85"/>
                    <measurement group_id="O4" value="1.0" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Difference in Change from Baseline in Knee Circumference at Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="3.20"/>
                    <measurement group_id="O2" value="3.8" spread="8.25"/>
                    <measurement group_id="O3" value="-1.4" spread="4.03"/>
                    <measurement group_id="O4" value="4.3" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) of NRS From 0-24 Hours, 0-48 Hours, and 24-48 Hours</title>
        <description>Numerical rating scale (NRS) at rest pain score (0 [no pain] to 10 [worst possible pain]) upon arrival at the PACU; at each in-hospital vital sign assessment beginning with the 2-hour assessment and ending with the 48-hour assessment; and the Day-7 follow-up visit. Summary is provided as area under the curve (AUC) of NRS from timepoint 0 to 24 hours, 0 to 48 hours, and 24 to 48 hours.</description>
        <time_frame>Preoperative; arrival in Post-Anesthesia Care Unit (PACU); 2, 4, 6, 8, 12, 16, 24, 36, 48 hours, Day 7</time_frame>
        <population>Efficacy analysis set: All subjects who received study drug and underwent planned surgery.</population>
        <group_list>
          <group group_id="O1">
            <title>DepoTXA 400mg</title>
            <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O2">
            <title>DepoTXA 800mg</title>
            <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O3">
            <title>DepoTXA 1200mg</title>
            <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
          </group>
          <group group_id="O4">
            <title>IV Tranexamic Acid (TXA)</title>
            <description>1 g of IV TXA at the end of surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of NRS From 0-24 Hours, 0-48 Hours, and 24-48 Hours</title>
          <description>Numerical rating scale (NRS) at rest pain score (0 [no pain] to 10 [worst possible pain]) upon arrival at the PACU; at each in-hospital vital sign assessment beginning with the 2-hour assessment and ending with the 48-hour assessment; and the Day-7 follow-up visit. Summary is provided as area under the curve (AUC) of NRS from timepoint 0 to 24 hours, 0 to 48 hours, and 24 to 48 hours.</description>
          <population>Efficacy analysis set: All subjects who received study drug and underwent planned surgery.</population>
          <units>scores on a scale*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5230.0" spread="3416.48"/>
                    <measurement group_id="O2" value="4723.0" spread="3242.87"/>
                    <measurement group_id="O3" value="5119.3" spread="2587.32"/>
                    <measurement group_id="O4" value="6876.3" spread="2560.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11375.1" spread="6159.89"/>
                    <measurement group_id="O2" value="12063.0" spread="3331.38"/>
                    <measurement group_id="O3" value="10859.5" spread="4761.97"/>
                    <measurement group_id="O4" value="13406.8" spread="5495.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(24-48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6145.1" spread="2786.30"/>
                    <measurement group_id="O2" value="7340.0" spread="1880.10"/>
                    <measurement group_id="O3" value="5740.3" spread="2244.90"/>
                    <measurement group_id="O4" value="6530.5" spread="2936.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening to postsurgical day 60</time_frame>
      <desc>An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans whether or not considered drug-related. An AE could therefore have been any unfavorable and unintended sign (eg, abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug without any judgment about causality. Serious AEs were defined as per clinicaltrials.gov.</desc>
      <group_list>
        <group group_id="E1">
          <title>DepoTXA 400mg</title>
          <description>Single injection of DepoTXA 400 mg into the joint space via catheter prior to capsular closure</description>
        </group>
        <group group_id="E2">
          <title>DepoTXA 800mg</title>
          <description>Single injection of DepoTXA 800 mg into the joint space via catheter prior to capsular closure</description>
        </group>
        <group group_id="E3">
          <title>DepoTXA 1200mg</title>
          <description>Single injection of DepoTXA 1200 mg into the joint space via catheter prior to capsular closure</description>
        </group>
        <group group_id="E4">
          <title>IV Tranexamic Acid (TXA)</title>
          <description>1 g of IV TXA at the end of surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Postprocedural hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution and investigator shall reasonably cooperate with Pacira to prepare abstract and manuscript reporting primary results within 90 and 120 days, respectively, of single and/or pooled analysis final CSR and shall publish no other trial results within 12 months after completion of final CSR. Institution shall submit all proposed written materials related to the trial ≥60 days before submission for presentation/publication. Pacira may embargo publication for an additional 90 days.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated on 27-Nov-2017 due to low enrollment; small sample sizes make data interpretation difficult.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pacira Medical Information</name_or_title>
      <organization>Pacira Pharmaceuticals, Inc.</organization>
      <phone>1-855-793-9727</phone>
      <email>MedInfo@pacira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

